FDA Investigator Tammy L Chavis

Tammy L Chavis has inspections in 1 countries as of 02 Nov 2023. Tammy L Chavis has collaborated with a combinined 3249 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
103
Last Inspection Date:
02 Nov 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America
Co-Investigator(s):
A Williams, Alicia M Mozzachio, Alla Kachko, PhD, Anastasia I Offordile, Anastasia M Shields, Anissa M Cheung, Anita R Michael, Ann L Demarco, Ann Marie Montemurro, Ann Marie Schofield, Anthony A Charity, Audrey Thereset Uy, Brandi L Garbutt, Brandy N Lepage, Brentley S Collins, Brian S Keefer, Burnell M Henry, Carol A Robles, CDR Jeremy L Wally, PhD, Chao Ming Tsai, Christian D Lynch (CDL), Christina J Sauder, PhD, Christina K Theodorou, Christopher J Adams, Craig D Zagata, Cynthia Jim, CSO, Cynthia White, Daniel J Min, Daniel T Lee, Darlene C Plank Turlington, Dauksism, Dave Hafner, David A Oluwo, David J Hafner, Dawn D Aiello, Deborah J Parris, Debra J Bennett, Debra L Pagano, Denise M Digiulio, Derek S Dealy, Djamila Harouaka, Donald L Lech, Donald W Myrick, Dr. Guang Gao, PhD, Dr. Mark J Seaton, PhD, Edward D Mcdonald, Eileen A Liu, Ellen Huang, Erika M Wilkerson, Erika V Butler, Erin L Mcfiren, Gayle S Lawson, Gene D Arcy, George Pyramides, Gerald W Kopp, Hala L Selby, Hala Lj Whetstone, Haruhiko Murata, Helen B Ricalde, Herrmann, J David Doleski, Jacob M Dyer, Jacqueline Mdiaz Albertini, James M Mason, James P Mcevoy, Jason M Sluzynski, Javier E Santos, Jean Blackston Hill, Jean Blackstone Hill, Jeannie R Mayberry, Joan A Loreng, Joan Adamo, Joanne Hajoway, Joanne Heim, Joanne M Hajoway, Joseph George, Joseph L Despins, PhD, Joseph T Dougherty, Juanita P Versace, Jude C Dikes, Judith A Paterson, Julianne C Mccullough, Junho Pak, Junho Park, Karyn M Campbell, Kathleen B Mihalik, Kathryn Carbone, MD, Kelly N Kerr, Kendra L Brooks, Kenneth M Gordon, Kimberly A Dux, Ko U Min, Kristen D Evans, Kristina J Donohue, Kristina L Conroy, Kyle S Hobson, Lauren N Barber, Lawrence Harmon, Jr, LCDR Margaret E Digennaro, Linda M Ross, Linda Thai, Lisa B Orr, Lisa Fecla, Lisa Feela, Lisa Feola, Lisa M Bellows, Lori P Peters, Lori S Lawless, LT John M Mastalski, LTJG Bradley E Benasutti, LTJG Lauren N Shade, Luella J Rossi, Luella Rossi, Luis A Dasta, Magdi A Ali, Marc A Jackson, Jr, Marcelo O Mangalindan, Jr, Marea K Harmon, Margaret M Sands, Maria A Reed, Marian E Major, PhD, Martha Sullivan Myrick, Matthew R Noonan, Maureen A Wentzel, Meredith L Sheridan, Michael A Taylor, Michael Curbag, Michael D Omeara, Michael Gurbarg, Michael J Nerz, Michael L Casner, Michele M Falchek, Mihaly S Ligmond, Mike M Rashti, Nicole K Trudel, Omotunde O Osunsanmi, Patricia D Gardner, Paula A Trost, Prabhu P Raju, Qiao Y Bobo, Rabin N Ghoshal, Rachael O Oyewole, Ralph A Erickson, Ramon E Martinez, Rebecca K Olin, Richard E Needham, Rita F Larocca Mahoney, Robert B Shibuya, MD, Robert D Tollefsen, Robert J Maffei, Robert W Jennings, Rochelle L Massey, Ronald A Stokes, Ronald T Nowalk, Rose M Ashley, Rw Mccullough, Sam Pepe, Scott E Norris, Sean D Duke, Seng Ching Hwang, Sheila Dreher Lesnick, Shelley L Waring, Shuang Tang, Simone E Pitts, State Agency, Stephanie Mangigian, MS/OSH, RN, Stephen D Brown, Stephen J Koniers, Steven A Rubin, Susan F Laska, MS, Susan M Jackson, Tekalign Wondimu, Temar Q Williams, Thomas E Friel, Tiffani D Wilson, Tiffani Wilson, Tina S Roecklein, Todd J Maushart, Tonya O Corbin, Vlada Matusovsky, Wei Wang, PhD, Whitney S Reynolds, Xiao Wang, Yvette I Henry, Yvette I Johnson, Yvonne C Mcknight

Tammy L Chavis's Documents

Publish Date Document Type Title
September, 2000 EIR Wyeth-Ayerst Pharmaceuticals, Inc - EIR, 2000-09-22
September, 2000 EIR Wyeth Division of Wyeth Pharmaceuticals, Inc. - EIR, 2000-09-21
January, 2004 FDA 483 PEL HEALTHCARE LLC - Form 483, 2004-01-09
May, 2001 EIR Noramco, LLC - EIR, 2001-05-08
October, 2003 EIR SPI Pharma, Inc. - EIR, 2003-10-23
February, 2003 FDA 483 Snow Pharmaceuticals, LLC - Form 483, 2003-02-06
June, 2005 EIR SPI Pharma Inc - EIR, 2005-06-20
May, 2001 FDA 483 Noramco, LLC - Form 483, 2001-05-08
June, 2005 FDA 483 Response SPI Pharma Inc - Form 483R, 2005-07-14
June, 2001 EIR Charles River Laboratories, Inc. - EIR, 2001-06-14
May, 2005 EIR Eurofins Lancaster Laboratories, Inc - EIR, 2005-05-12
January, 2004 FDA 483 Response PEL HEALTHCARE LLC - Form 483R, 2004-01-22
April, 2002 EIR Airgas Usa, LLC - EIR, 2002-04-10
February, 2003 EIR Procter and Gamble Dover Wipes Company - EIR, 2003-02-12
January, 2003 FDA 483 SPI Pharma Inc - Form 483, 2003-01-27
January, 2002 EIR AstraZeneca Pharmaceuticals LP - EIR, 2002-01-14
June, 2005 FDA 483 SPI Pharma Inc - Form 483, 2005-06-20
September, 2000 FDA 483 Wyeth-Ayerst Pharmaceuticals, Inc - Form 483, 2000-09-22
February, 2004 EIR Eurofins Lancaster Laboratories, Inc - EIR, 2004-02-26
June, 2004 FDA 483 AstraZeneca Pharmaceuticals LP - Form 483, 2004-06-24
June, 2001 FDA 483 Charles River Laboratories, Inc. - Form 483, 2001-06-14
April, 2002 FDA 483 Airgas Usa, LLC - Form 483, 2002-04-10
April, 2003 EIR Pharmalog Inc. Pharmaceutical Services - EIR, 2003-04-01
June, 2001 FDA 483 Response Charles River Laboratories, Inc. - Form 483R, 2001-07-10
January, 2004 EIR PEL HEALTHCARE LLC - EIR, 2004-01-09
May, 2003 EIR Merck Sharp & Dohme LLC - EIR, 2003-05-14
August, 2002 EIR Airgas Usa, LLC - EIR, 2002-08-23
July, 2000 FDA 483 IGI, Inc. - Form 483, 2000-07-05

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more